Jul 2026· Journal of Immunology· Vol 215· 0 citations
TL;DR
An expanded and standardized framework that harmonizes human systems vaccinology datasets using ImmPort metadata, and develops an automated pipeline to integrate experimental design, clinical metadata and serological response data from ImmPort with linked transcriptional profiling data from GEO is presented.
Abstract
Vaccines are among the most impactful public health interventions. Systems vaccinology leverages high-dimensional omics data to elucidate mechanisms of vaccine-induced immunity, but these data are often fragmented across studies with heterogeneous metadata, limiting cross-study analyses. The NIH/NIAID Human Immunology Project Consortium (HIPC) previously addressed this challenge by releasing the Immune Signatures Data Resource (ISDR). Here, we present ISDR 2.0, an expanded and standardized framework that harmonizes human systems vaccinology datasets using ImmPort metadata. ISDR 2.0 broadens vaccine coverage and introduces a robust, reproducible analysis pipeline for consistent data processing, quality control, and immune response interpretation.
We developed an automated pipeline to integrate experimental design, clinical metadata and serological response data from ImmPort with linked transcriptional profiling data from GEO. Using these standardized metadata, we constructed a MultiAssayExperiment object that unifies molecular data with subject demographics and vaccine details for seamless analysis.
The ISDR 2.0 provides a harmonized collection of 9,638 gene expression samples from 2,544 subjects across 51 studies, covering 36 different vaccines. Through the newly developed automated harmonization pipeline, this comprehensive dataset incorporates extensive RNA-seq data, offering a computationally ready platform with enhanced statistical power for identifying pan-vaccine immune signatures.
The ISDR 2.0 provides the systems vaccinology community with a standardized dataset for analyzing human vaccine response data. By harmonizing a large number of samples, standardizing metadata via ImmPort, and processing data through a reproducible pipeline, this resource will accelerate the identification of robust immune signatures and enable the development of powerful, predictive models critical for next-generation vaccine design.
NIH grants U01AI167892
Vaccines and Immunotherapy (VAC)
Pre-existing antigen-specific antibody titers and baseline monocyte frequencies are identified as the most consistent predictors of post-vaccination immunity, highlighting the dominant role of individual immune setpoints.
Pramod Shinde, Lisa Willemsen, Jiyeun Lee et al.· bioRxiv· 0 citations
Background: Whole-blood transcriptomic profiling can capture systemic immune-response alterations associated with COVID-19 and may support host-response-based classification. However, evidence regarding the discriminatory value of targeted immune-gene panels remains limited, and in small, high-dimensional datasets, the...
Z. Yilmaz, Z. Kucukakcali, Sami Akbulut· Viruses· 0 citations
Transcriptomic data reveal how gene expression changes in inflammatory diseases. Thousands of these datasets are now public and free to reuse. This working paper reviews the main resources and methods for this field. It uses inflammatory bowel disease as a running example. The paper has four goals. First, it maps the g...
Bing Chen· World Journal of Clinical Sc...· 0 citations
The rapid deployment of mRNA vaccines during the COVID-19 pandemic exposed limitations in traditional pharmacovigilance systems, including delayed reporting, high underreporting rates, and inability to calculate true incidence. Machine learning (ML) offers new pathways to overcome these challenges by integrating multi-...
Yu-Long He, Yan Mao, Xin-Yue Wang· BMC Medical Informatics and...· 0 citations
CEDAR’s current capabilities, report on progress in curation, database development, and tool availability, and outline the opportunities and challenges ahead for expanding its scope and utility to the cancer research community are described.
Zeynep Koşaloğlu-Yalçın, Ibel Carri, Daniel Marrama et al.· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.